mRNA 2.0 Is Not a Science Story — It’s a $31 Billion Platform Bet That Most Pipelines Aren’t Priced For
Nature Reviews Drug Discovery maps mRNA's expansion into enzyme replacement and cancer immunotherapy—here's what it means for pipeline valuations...